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Gonc¸alo R. Abecasis2,*Thank you very much. I would first like to thank the
Awards Committee, The Society, and all of you who are
here this morning. For the past 15 years, I have treasured
coming to this meeting, which is always full of energy,
ideas, and brilliant scientists. To be honest, I find it hard
to see myself in Aravinda Chakravarti’s and Michael
Boehnke’s kind description of me, and in the next few
minutes, I will probably disprove their claim that I am a
good communicator. I stand before you trembling.
If you will indulge me, I would like to tell you about the
work I have done in human genetics and about what I
have learned in the process. The past several years have
been remarkable in that they’ve shown exponential
growth in the size of human genetic studies. While pre-
paring this talk, I reviewed the studies in which I have
been involved since attending my first American Society
of Human Genetics Annual Meeting. If we use the total
number of genotypes characterized as a measure of study
size, these studies have grown in size by a factor of about
4 every year, about 1,000 every 5 years, and about
1,000,000 every 10 years. It’s easy to be hopeful and
imagine that this pace might continue for several years.1This article is based on the address given by the author at the meeting of The
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The AmeFor someone working on computational methods, this
exponential growth presents many opportunities and
challenges. It has also been a lot of fun, and I feel all of
us are extremely lucky to witness and participate in this
era of human genetics.
I started my career in human genetics at the Wellcome
Trust Center for Human Genetics at a time when com-
plex-trait studies where shifting from linkage to associa-
tion. I originally started working in the lab on developing
methods for ‘‘high-throughput’’ SNP discovery and geno-
typing. At that time, our ‘‘high-throughput’’ methods
enabled characterization of perhaps hundreds of geno-
types per day. Those rudimentary ‘‘high-throughput’’
methods enabled us to generate data at a pace that made
analysis with the then-available tools cumbersome. My
first paper, published in The American Journal of Human
Genetics,1 described methods for analyzing association in
samples that typically had been collected for family link-
age studies. A companion computer program was able to
handle hundreds or thousands of genetic markers and
could examine the evidence for association in samples
of families or unrelated individuals. During my time at
Oxford, I was greatly aided by great colleagues and two
very generous mentors, Professors William Cookson and
Lon Cardon. They gave me the opportunity to explore
interesting datasets and the flexibility to pursue my own
ideas, and they shared their time generously.
Soon after, I worked on a method for rapid pedigree
analysis,2 which Mike described charitably in his introduc-
tion. As I reminisce on this work, I would like to share two
impressions with you. First, it is clear that I was greatly
aided by Leonid Krulyak and Mark Daly’s earlier work3
on GeneHunter. (Mark is the 2014 co-recipient of the
Curt Stern Award.) Their work served me as a useful guide
and reference, allowing me to validate implementations of
my new method and sparing me many sleepless nights.
Second, I noticed an evaluation we’d carried out with a
10-SNP dataset generated by Bernard Keavney and col-
leagues.4 At the time, our new very fast and memory-
efficient approach enabled analyses of that dataset to be
completed in ~40 s. That might have been an advance
then, but it also represents a level of performance that is
unacceptable now that datasets can include information
on millions of genetic markers. Time will continue to putAmerican Society of Human Genetics (ASHG) on October 20, 2014, in San
website.
, Ann Arbor, MI 48109, USA
commons.org/licenses/by-nc-nd/4.0/).
y of Human Genetics. All rights reserved.
rican Journal of Human Genetics 96, 363–366, March 5, 2015 363
our best computational approaches to the test and demand
that we continually improve or replace them.
In part because of this early work on computational
methods for SNP analysis, I had the privilege of partici-
pating in many early efforts characterizing variation at a
genomic scale, starting with the International HapMap
Consortium. There, I encountered several greats of modern
human genetics, includingMark Daly (again) and also Ara-
vinda Chakravarti, Peter Donnelly, and David Altshuler.
Aided by a second set of remarkable characters, I soon pro-
ceeded to applymethods to characterize genomic variation
at scale to study a variety of complex human traits and
diseases. Among the remarkable colleagues with whom I
worked at the time, a few stand out: Michael Boehnke,
Francis Collins, Anand Swaroop, David Schlessinger, Ser-
ena Sanna, Joel Hirschhorn, James Elder, Sekar Kathiresan,
and Cristen Willer.
For me, one of the remarkable lessons from that time
was to learn that by combining data and results across
studies, we could rapidly accelerate the pace of discovery.
This lesson was helped by the discovery of genotype
imputation5,6 and by new tools for meta-analysis of
genetic association studies.7 Genotype imputation uses
stretches of chromosome shared between apparently unre-
lated individuals to reconstruct genotypes at any genetic
marker and greatly facilitates comparisons between
studies relying on different marker sets. In our first
genome-wide association study (GWAS) meta-analysis,
aided by imputation, we combined three studies each
with little evidence of new loci and discovered 17 loci
associated with blood lipid levels.8 Through advances in
genotyping, imputation, and meta-analysis, these meta-
analyses can now include hundreds of thousands of indi-
viduals. It is now straightforward to generate very large
catalogs of loci associated with complex traits. It is also
clear that, even 10 years ago, these catalogs would have
been a great achievement and perhaps hard to imagine.
Still, most of us are now unsatisfied with simply cata-
loguing complex-trait loci and believe it is very important
to move on to the next phase, which is to translate these
catalogs into insights about human disease biology and
medicine.
At the same time that interesting things happen in ge-
netics, other interesting things happen in the rest of our
lives. I would like to share with you a memory from this
time, when we were conducting our early genome-wide
analyses of genetic variation and its relationship with
many human traits. I visited Mark Daly in Boston, and
he invited me to join him for dinner at the end of the
day. We walked out of his office, walked through a grocery
store near Massachusetts General Hospital, and picked up a
truly large cut of salmon. I must have told Mark we’d have
trouble finishing such a big fish, but he was undaunted. He
drove us home and introduced me to Mary Pat and four
charming children. Mark then proceeded to prepare and
cook the fish.When dinner was ready, Mark’s four wonder-
ful kids helped make the entire salmon disappear quickly.364 The American Journal of Human Genetics 96, 363–366, March 5It was quite an inspiration to see a very successful scientist
get home in time to cook dinner and share it with his
family.
Studies of human genetic variation have been gradually
shifting from arrays to full genome sequencing. One of the
first projects to explore the possibilities was the 1000
Genomes Project, which also showed me how different
very competitive, very able people could come together
to make special things happen. If you knowmy three proj-
ect co-leaders—David Altshuler, Gil McVean, and Richard
Durbin—you’ll know that they are extremely competitive,
extremely able scientists. Working together with them
made the project a memorable experience for me.
My experience early in the project greatly influenced
and, indeed, changed how I think about the analysis of
large complex datasets. After assembling all the whole-
genome sequence data collected in the first phase of the
project,9 we set out to identify an optimal strategy for
converting the raw sequence data (which consisted of
many short sequence fragments with many errors) into
high-quality lists of variants and genotypes for the indi-
viduals we were studying. I was sure that we would be
able to compare several alternative strategies and agree
on one superior strategy—ideally, this optimal strategy
would be the one developed by my group at the Univer-
sity of Michigan.10 Instead, we were deadlocked. Each of
the analyses carried out by teams at the Broad Institute,
Michigan, and the Wellcome Trust Sanger Institute was
optimal in some way. Eventually, we resolved the problem
not by deciding on which of these strategies was superior
but by combining their respective solutions into a
consensus or ensemble prediction. Remarkably, this
consensus solution was better in all respects than the
solutions each of our teams had spent time crafting and
optimizing. The advantages of ensemble predictors are
common to many areas of computation, biology, and
society—but I had not come across them in such a direct
way before.
Most recently, we have applied the same methods and
ideas that were used for sequencing the 1000 Genomes
Project participants to other interesting studies, especially
ones where rich health and medical information is
available. One of the most interesting of these has been
our ongoing study of the genetics of isolated Sardinian
populations11 in collaboration with a very able team of
Sardinian geneticists led by Francesco Cucca. To reduce
cost, we sequenced each genome at low coverage.10
Although this sequencing strategy is not well suited to
the analysis of a single genome, it has a remarkable prop-
erty: as more and more individuals are sequenced, we are
able to interpret available sequence data for each genome
better. In practice, this means that as we sequence more
genomes, we are able to examine progressively more ge-
netic variants and, at the same time, to more accurately
characterize the genotypes at each variant. There is not
enough time to describe the results in detail, but given
that you will soon hear from William Allan Award winner, 2015
Stuart Orkin—who has done remarkable work studying
the causes and mechanisms of the thalassemias and sickle
cell anemia—I want to highlight one interesting and
unpublished observation from our studies of low-density
lipoprotein (LDL) cholesterol, a strong risk factor for car-
diovascular disease. When we sequenced 2,000 Sardinians
and examined the list of loci associated with LDL choles-
terol, we observed many of the usual suspects seen in
other GWASs (including the loci where APOB, APOE,
LDLR, PCSK9, and SORT1 reside). Remarkably, we were
also able to show a very strong effect on LDL cholesterol
levels for the p.Gln39* variant in HBB—a variant that
Dr. Orkin will know well as the cause of b-thalassemia
on the island. Our analysis suggests that p.Gln39* is also
one of the biggest drivers of LDL cholesterol levels in the
Sardinian population. Association between the HBB locus
and LDL cholesterol is not typically seen in GWASs
because the loss-of-function alleles, which are typically
rare and population specific, cannot be well captured by
standard arrays.
The secret of success is to have many able collaborators,
mentees, and students. I certainly wouldn’t be here
without all their criticism, encouragement, ideas, and
hard work. I am truly grateful to each of them.
It is probably premature, but also tempting, to reminisce
on the lessons I have learned. I certainly have many more
to learn. I share the lessons I have learned in the hopes
that they might be helpful to audience members who are
starting their careers in our wonderful field of human
genetics.
1. One person and a good idea can make a difference.
As human genetic studies increase in size and
complexity, it is sometimes easy to get disheartened
and think that one can’t compete with much larger
teams, studies, and budgets. Instead, we should
remember that novel algorithmic insights can often
improve computational performance by several or-
ders of magnitude and thus enable even small teams
to beat much larger and better resourced teams. Even
more important, approaching a problem from a new
angle can lead to completely new, previously over-
looked answers and insights.
2. The best students, postdocs, and collaborators generally
know something that you don’t. This insight is a bit
disconcerting at first. When evaluating a prospective
student, postdoc, or collaborator (which you should
do carefully!), it is not sufficient to rank them accord-
ing to what you know. Instead, it is perhaps most
important to explore how much of what they
know is something you don’t and how well you
might complement each other. Many accomplish-
ments depend on just the right partnership and
would not be possible otherwise.
3. Take the time to be amazed. Drop everything, and
explore a new idea. Some of my colleagues consider
this a personality defect (we complement eachThe Ameother!), but I believe that on occasion it is important
to drop the day-to-day things that one should be do-
ing and instead take the time to explore something
new, interesting, and fun. In many ways, that is
where the fun of science, of genetics, and of discov-
ery comes from.
4. Keep learning. There are so many ideas out there.
Perhaps the truth in this statement is most obvious
when attending The Society’s annual meetings. It is
really a privilege to come to this meeting and to see
so many developments in human genetics. I really
find it surprising that, with all the great science being
presented at this year’s meeting, I would have been
lucky enough to be selected for the 2014 Curt Stern
Award.
5. The most valuable tools and algorithms are often
extremely simple. It’s sometimes tempting to think
that great discoveries are complicated. I have learned
over time that sometimes our most valuable discov-
eries are very simple. They just need to be applied
and tried at the right time.
Looking ahead, it seems clear that we’ll sequence thou-
sands of genomes and that we’ll discover better computa-
tional methods and strategies for managing, analyzing,
and interpreting the resulting data. Still, some of the
biggest challenges in our field are not about the scale of
experiments or computational efficiency. In my view,
there remain big challenges in how we enable different
scientists to interact with data, understand it, choose
powerful study designs, and answer important questions.
As the field of human genetics and its applications get
more complex and more diverse, I feel that we need to
spend quite a bit of time facilitating communication of
our findings to experts in other disciplines and across
the different subfields in our society.
To conclude, Iwanted to take amoment to thankmy fam-
ily. The past 10 years have also been a very interesting time
for them. A little over 10 years ago, I married CristenWiller,
whom I met during my doctoral studies at Oxford. Cristen
has been wonderfully encouraging, supportive, and pa-
tient. Those of you who know her will know that she is
also an accomplishedgeneticist andmember of The Society.
We now have four kids, and another one is due in March.
They are a little smaller than Mark’s, so they’re probably
not as much of a handful, but they really make my days at
theofficeworthwhile. I encourage anybodywho is thinking
about a career in genetics not to be concerned that it gets in
the way of family life. Don’t trade. Do both.
Thank you all very much.Acknowledgments
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